Skip to NavigationSkip to content

ProStrakan begins pan-European launch campaign with Tostran

Published on 11/06/07 at 03:43pm

ProStrakan has unveiled Tostran in the UK, the first in a pan-European programme of product launches.

Tostran is a testosterone replacement gel for male hypogonadism and an important product for the Scottish specialty pharmaceutical company.

Chief executive Dr Wilson Totten said: "Tostran represents a high-potential, high- value opportunity for us and its UK launch is a major milestone in the group's development.

"While the UK is our largest single market, we will continue the roll-out of this product across the rest of Europe during the remainder of 2007 and anticipate that it will make a significant contribution to the group's future revenues."

Tostran is one of five products ProStrakan plans to launch in Europe over the next 18 months.

Its cheomotherapy-induced nausea and vomiting treatment Sancuso, cancer pain treatment Rapinyl and Dropridol for post-operative nausea and vomiting are waiting approval from regulators and further launches are also planned for both its chronic anal fissure treatment Rectogesic and Tostran. The company also plans to apply to the FDA for a US licence for the latter, which it expects to file with the regulator during 2008.

The testosterone replacement market is currently valued at €60m in Europe.

In the US, where the market is significantly more developed, it is worth $500 million.

It is estimated that 6-12% of men over the age of 40 have low testosterone levels with a number of associated clinical symptoms including: reduced energy levels, reduced sleep, moodiness, weight gain, and erectile dysfunction (ED).

A recent study showed that men with type II diabetes frequently have low testosterone levels.

Early pilot studies have shown that testosterone replacement therapy in testosterone-deficient men with type II diabetes can lead to improvements in insulin sensitivity, glycaemic control, and abdominal obesity, thereby potentially reducing cardiovascular risk.

In a study of testosterone gel in men with both low testosterone and ED, 63.3% gained normal erectile function and also found they had significant increases in sexual desire.

Tostran 2% gel is a replacement therapy for male hypogonadism when testosterone deficiency has been confirmed by clinical symptoms and laboratory analyses.

The UK launch will be supported by ProStrakan's 60-strong salesforce.

Tostran was launched in Sweden in 2005, where it now accounts for more than 30% of the testosterone gel market. The product is in the process of being introduced across Europe and is expected to be available in all major European markets by the end of 2007.

ProStrakan, which has its headquarters and R&D activities in Galashiels in Scotland, is one of Europe's fastest growing specialty pharmaceutical companies.

In addition to the UK, the company has commercial operations in Germany, France, Spain, Sweden and the BeNeLux countries.

In 2006, the company's revenues increased by 22% to £38.5 million and sales of its lead product, calcium and vitamin D deficiency treatment Adcal-D3, rose by 29% to £13 million.

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches